1 May 2024 - The outcomes from the February 2024 PTAC meeting are now available.

The PTAC considered the following funding applications:

• Esketamine hydrochloride (Spravato) for depression - rejected
• Sildenafil citrate and tadalafil for erectile dysfunction - recommendation
• Naloxone hydrochloride (Nyxoid) for opioid overdose - recommendation
• Faricimab (Vabysmo) for macular oedema - recommendation (cost neutral)
• Faricimab (Vabysmo) for age-related macular degeneration - recommendation (cost neutral)

Read PTAC minutes